Interventional Oncology Devices Market By Product (Embolization Devices, Ablation Devices, and Support Devices), By Procedure (Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy, and Transcatheter Arterial Embolization/Bland Embolization), By Cancer (Liver Cancer, Lung Cancer, Bone Cancer, and Kidney Cancer), and By Region - Trends, Analysis and Forecast till 2030

Oncology deals with the diagnosis, prevention, treatment of cancer. A physician who works in the field of oncology is called an oncologist. Various ultrasound or radiological methods such as endoscopy, biopsy, X-ray, MRI, CT scanning, PET scanning, and others are used to diagnose cancer. The interventional device is a type of cancer care which is done with minimally invasive procedures, minimal complications, and reduce the risk of infection, shorter hospital stay, lesser pain, and faster recovery time as compared to the conventional open surgeries. The global interventional oncology devices market accounted for US$ 4.2 billion in 2025 and is projected to register a moderate CAGR over the forecast period.

Growing incidence and increasing prevalence of cancer globally among individuals is the major factor driving the growth of the global interventional oncology devices. According to data published by WHO, cancer acts as the second leading cause of death worldwide and accounted for 9.6 million deaths in 2018. Approximately 70% of deaths occur in low- and middle-income countries from cancer. Also, high preference for minimally invasive surgical procedures, favourable reimbursement scenario for interventional oncology treatment in developed countries, availability of government and private funding, and others. These factors are also expected to boost the growth of the global market over the forecast period. However, the lack of clinical pieces of evidence for localized region treatment and increasing financial burden on industry players with a high number of product recalls is restraining the growth of the target market. Nevertheless, increasing merger and acquisitions among the industry players along with product launches are expected to create lucrative growth opportunities for the target market over the forecast period.

The global interventional oncology devices market is segmented based on the product, procedure, cancer, and region.

Based on the product, the global interventional oncology devices market is segmented into embolization devices, ablation devices, and support devices. Based on procedure, the target market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization, transcatheter arterial radioembolization/selective internal radiation therapy, and transcatheter arterial embolization/bland embolization. Based on cancer, the global is classified into liver cancer, lung cancer, bone cancer, and kidney cancer.

Regional Insights:

On the region, the global interventional oncology devices market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2018, North America accounted for the highest share of the global interventional oncology market, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. However, Asia-Pacific is expected to be the fastest-growing regional market owing to growing government focus on the healthcare sector and accelerated economic growth of many countries in this region. Additionally, rising incidence & prevalence of cancer; government initiatives towards the development of healthcare facilities, a growing number of middle-class population and their level of disposable income are the factors boosting the growth of the target market. Moreover, the growing ageing population and increasing health insurance penetration in the region are also propelling the growth of the Asia-Pacific interventional oncology market

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global interventional oncology devices markets report based on Product, Procedure, Cancer and Region.                                 

Interventional oncology devices markets, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of the Middle East & Africa

The key players operating the global interventional oncology devices market include AngioDynamics Inc., Becton, Dickinson and Company, Boston Scientific Corporation, BTG PLC, HealthTronics Inc., Medtronic PLC, Sirtex Medical Ltd., Merit Medical Systems Inc., and Terumo Corporation. Prominent players operating in the target market are focusing on strategic partnerships as well as the launching of the products to gain a competitive edge in the target market. BD is presently the largest shareholder in the target market. In 2018, the company’s contribution was valued to be 23.06% of the global interventional oncology devices market value. However, companies namely Terumo Corporation, Boston Scientific Corporation, and Merit Medical Systems, Inc. are projected to witness impeccable growth in the forecast period. 

• AngioDynamics, Inc.
• Becton, Dickinson and Company
• Boston Scientific Corporation
• BTG PLC
• HealthTronics Inc.
• Medtronic PLC